The headline beat is misleading due to non-recurring items. Monitor the Q3 2026 earnings for organic revenue growth in diagnostics and pharmaceuticals, and track cash burn rate. The raised full-year guidance provides a positive narrative, but the underlying business trends remain weak.
Price Chart
Executive Summary
OPKO Health reported Q2 2026 revenue of $163.5M, above the $131.2M consensus estimate, and a net loss of $0.01 per share, significantly beating the consensus estimate of -$0.11. The beat was driven by a $29.4M non-cash revenue recognition from shares received in the Nicoya agreement amendment and a $18.1M earnout from the Labcorp asset sale, masking ongoing weakness in core diagnostics revenue, which fell to $74.5M from $101.1M a year ago. Full-year revenue guidance was raised to $560M-$585M from the prior $530M-$560M range, but the company remains unprofitable with an operating loss of $7.0M, and the quality of the beat is low due to its reliance on non-recurring items.
Key Financial Metrics
Key Facts
- Q2 2026 total revenue of $163.5M vs $156.8M YoY, beating consensus of $131.2M.
- Net loss of $0.01 per share vs consensus -$0.11, a 90.9% beat.
- Revenue beat driven by $29.4M non-cash revenue from Nicoya equity stake and $18.1M Labcorp earnout.
- Core diagnostics revenue declined to $74.5M from $101.1M YoY, impacted by the Labcorp asset sale.
- Full-year 2026 revenue guidance raised to $560M-$585M from prior $530M-$560M.
- Cash burn continues: cash & equivalents fell to $300.8M from $369.1M at year-end 2025.
- Operating loss improved to $7.0M from $60.0M YoY, but still negative.
Financial Impact
Revenue beat of $32.3M vs consensus, but $29.4M of that is non-cash from a licensing amendment. Core operations remain loss-making.
Risk Factors
- Core diagnostics revenue continues to decline post-Labcorp sale.
- Cash burn of ~$68M in H1 2026 reduces financial flexibility.
- Dependence on non-recurring items (Nicoya, Labcorp earnout) for revenue growth is unsustainable.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-318069 |
| Document: opk-20260727.htm | 0001193125-26-318069 |
| Document: 0001193125-26-318069-index-headers.html | 0001193125-26-318069 |
| Document: 0001193125-26-318069-index.html | 0001193125-26-318069 |
| Document: 0001193125-26-318069.txt | 0001193125-26-318069 |
| 8-K Data (Synthetic) | 0001193125-26-318069 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 27, 2026 9w ago | 8-K | $1.65 $1.49 | ▼ −9.70% | ▼ −13.08% | $1.56 (−5.45%) |
Jul 23, 2026 10w ago | Press Release | $1.17 $1.46 | ▲ +24.79% | ▲ +21.48% | $1.56 (+33.33%) |
Jun 15, 2026 15w ago | Press Release | $1.40 $1.23 | ▼ −12.14% | ▼ −11.39% | $1.56 (+11.43%) |
May 15, 2026 20w ago | DEFA14A | $1.13 $1.39 | ▲ +23.01% | ▲ +21.43% | $1.56 (+38.05%) |
Apr 30, 2026 22w ago | Press Release | $1.13 $1.43 | ▲ +26.55% | ▲ +21.58% | $1.56 (+38.05%) |
Apr 22, 2026 23w ago | Press Release | $1.23 $1.15 | ▼ −6.50% | ▼ −9.67% | $1.56 (+26.83%) |
Apr 21, 2026 23w ago | Press Release | $1.23 $1.15 | ▼ −6.50% | ▼ −9.67% | $1.56 (+26.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access